Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-19

Awesome write-up mate however I think you left out one catalyst:

Phase 1 data readouts for IHL-675A'S three applications

I remember when 42X phase one readouts took place we saw a nice little appreciation in share price, and that was for a 10bn total addressable market p.a.

675-A's total addressable market is north of 120bn USD p.a.

It is definitely worth noting that PH1 trials aren't always seen as that significant to the overall market, but other times they are taken with strong enthusiasm, I'm glad they're due before H1 of this year, so it's a nice near term catalyst. If it will have any strong impact on the share price is anyone's guess in this tumultuous market. But I personally think it might be 2023's driver just as 42X in 2021.

Hopefully it brings us back to the 25c milestone and some of those options get executed, which when you contrast with other speculative stocks in the market outside of biotech it's not a far reach...

good luck all!!